Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -110.85% is in line with its 5-year average of -101.88%, around the middle of its 5-year range (-161.77%–-53.11%).
3.17% below its 12-month average of -107.44%.
Reported quarterly return on assets; no daily interpolation. Q3 FY2026 (2026-06-30): -42.51%.
RETURN ON ASSETS (ROA)
-110.85%
RETURN ON ASSETS (ROA) AVG TTM
-107.44%
RETURN ON ASSETS (ROA) AVG 3Y
-115.17%
RETURN ON ASSETS (ROA) AVG 5Y
-101.88%
RETURN ON ASSETS (ROA) AVG 10Y
-75.73%
RETURN ON ASSETS (ROA) AVG 15Y
-86.81%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-3.17%
CURRENT VS 3Y AVG
+3.75%
CURRENT VS 5Y AVG
-8.80%
CURRENT VS 10Y AVG
-46.37%
CURRENT VS 15Y AVG
-27.69%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-30.47%
median of 682 covered companies
CURRENT VS SECTOR MEDIAN
-263.80%
vs the sector median at left
Edesa Biotech, Inc.
Market Cap
$37.28M
Return on Assets (ROA)
-110.85%
TTM Avg
-107.44%
3Y Avg
-115.17%
5Y Avg
-101.88%
Market Cap
$36.61M
Return on Assets (ROA)
-120.78%
TTM Avg
-168.59%
3Y Avg
-147.82%
5Y Avg
-131.31%
Market Cap
$38.16M
Return on Assets (ROA)
-26.45%
TTM Avg
-127.88%
3Y Avg
-142.31%
5Y Avg
-121.77%
Market Cap
$36.05M
Return on Assets (ROA)
-103.00%
TTM Avg
-39.81%
3Y Avg
-17.36%
5Y Avg
-12.69%
Market Cap
$38.97M
Return on Assets (ROA)
-13.65%
TTM Avg
-40.30%
3Y Avg
-22.41%
5Y Avg
-15.81%
Market Cap
$35.15M
Return on Assets (ROA)
-136.91%
TTM Avg
-90.70%
3Y Avg
-79.79%
5Y Avg
-214.88%
Market Cap
$34.84M
Return on Assets (ROA)
118.69%
TTM Avg
-31.86%
3Y Avg
-49.56%
5Y Avg
-43.59%
Market Cap
$39.90M
Return on Assets (ROA)
11.01%
TTM Avg
4.71%
3Y Avg
-17.75%
5Y Avg
-20.00%
Market Cap
$39.92M
Return on Assets (ROA)
-53.81%
TTM Avg
-31.90%
3Y Avg
-23.26%
5Y Avg
-21.62%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Edesa Biotech, Inc. (EDSA) | $37.28M | -110.85% | -107.44% | -115.17% | -101.88% |
| Elicio Therapeutics, Inc. (ELTX)vs › | $36.61M | -120.78% | -168.59% | -147.82% | -131.31% |
| Incannex Healthcare Limited (IXHL)vs › | $38.16M | -26.45% | -127.88% | -142.31% | -121.77% |
| DocGo Inc. (DCGO)vs › | $36.05M | -103.00% | -39.81% | -17.36% | -12.69% |
| Harvard Bioscience, Inc. (HBIO)vs › | $38.97M | -13.65% | -40.30% | -22.41% | -15.81% |
| BriaCell Therapeutics Corp. (BCTX)vs › | $35.15M | -136.91% | -90.70% | -79.79% | -214.88% |
| Elutia Inc (ELUT)vs › | $34.84M | 118.69% | -31.86% | -49.56% | -43.59% |
| Nephros, Inc. (NEPH)vs › | $39.90M | 11.01% | 4.71% | -17.75% | -20.00% |
| Metagenomi, Inc. Common Stock (MGX)vs › | $39.92M | -53.81% | -31.90% | -23.26% | -21.62% |
| Accuray Incorporated (ARAY)vs › | $34.46M | -11.09% | -5.71% | -4.17% | -3.19% |
ROA
-110.8%
ROE
-160.1%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-09-30 | -53.11% |
| 2024-09-30 | -161.77% |
| 2023-09-30 | -94.20% |
| 2022-09-30 | -151.60% |
| 2021-09-30 | -91.49% |
| 2020-09-30 | -59.13% |
| 2019-09-30 | -47.59% |
| 2018-09-30 | -42.78% |
| 2017-09-30 | -65.16% |
| 2016-09-30 | -38.85% |
| 2015-09-30 | -27.37% |
| 2014-08-31 | -58.31% |
| 2013-08-31 | -174.86% |
| 2012-08-31 | -336.60% |
| 2011-08-31 | -149.16% |
| 2010-08-31 | -20.39% |
| 2009-04-30 | -30.48% |
| 2008-04-30 | 0.00% |
